Method of in situ gene sequencing

Patent metadata

Field	Value
Publication number	US-12359253-B2
Application number	US-201917045734-A
Country	US
Kind code	B2
Filing date	Apr 4, 2019
Priority date	Apr 9, 2018
Publication date	Jul 15, 2025
Grant date	Jul 15, 2025

Abstract

Provided herein are devices, methods, and systems for in situ gene sequencing of a target nucleic acid in a cell in an intact tissue. Methods of screening a candidate agent to determine whether the candidate agent modulates gene expression of a nucleic acid in a cell in an intact tissue are also provided herein.

First claim

What is claimed is:

1. A method for identifying a nucleic acid in a cell within a tissue, comprising:
(a) contacting the tissue with at least a pair of oligonucleotides under conditions to allow for specific hybridization of the pair of oligonucleotides to the nucleic acid, wherein the pair of oligonucleotide comprises:
(i) a first oligonucleotide, wherein the first oligonucleotide comprises a first complementarity region, a second complementarity region, and a third complementarity region; and
(ii) a second oligonucleotide, wherein the second oligonucleotide comprises a fourth complementarity region, a fifth complementarity region, and a sixth complementarity region; and
wherein the first complementarity region is complementary to a first portion of the nucleic acid, the second complementarity region is complementary to the fourth complementarity region, the third complementarity region is complementary to the sixth complementarity region, the fifth complementarity region is complementary to a second portion of the nucleic acid, wherein the first complementarity region and fifth complementarity region are hybridized to the nucleic acid;

(b) performing an amplification reaction on the nucleic acid having the pair of oligonucleotides hybridized thereto to yield one or more amplicons, wherein the one or more amplicons are embedded in a hydrogel; and
(c) imaging the one or more amplicons to identify the nucleic acid.

2. The method of claim 1 , further comprising, subsequent to (b), clearing the tissue of a plurality of cellular components.

3. The method of claim 2 , wherein the cellular components comprise lipids, proteins, or any combination thereof.

4. The method of claim 1 , wherein the pair of oligonucleotides are denatured by heating before contacting the tissue.

5. The method of claim 1 , wherein the cell is present in a population of cells.

6. The method of claim 5 , wherein the population of cells comprises a plurality of cell types.

7. The method of claim 1 , wherein the tissue is fixed and permeabilized with a single solution.

8. The method of claim 1 , wherein the nucleic acid is ribonucleic acid (RNA).

9. The method of claim 1 , wherein the nucleic acid is messenger RNA.

10. The method of claim 1 , wherein the nucleic acid is DNA.

11. The method of claim 1 , wherein the second oligonucleotide is provided as a closed nucleic acid circle.

12. The method of claim 1 , wherein:
(i) the second oligonucleotide comprises a padlock probe,
(ii) the first complementarity region of the first oligonucleotide has a length of 19 nucleotides to 25 nucleotides,
(iii) the second complementarity region of the first oligonucleotide has a length of 3 nucleotides to 10 nucleotides,
(iv) the third complementarity region of the first oligonucleotide has a length of 3 nucleotides to 10 nucleotides,
(v) the fourth complementarity region of the second oligonucleotide has a length of 3 nucleotides to 10 nucleotides,
(vi) the fifth complementarity region of the second oligonucleotide has a length of 19 nucleotides to 25 nucleotides,
(vii) the sixth complementarity region of the second oligonucleotide has a length of 3 nucleotides to 10 nucleotides,
(viii) the fourth complementarity region of the second oligonucleotide comprises a 5′ end of the second oligonucleotide,
(ix) the sixth complementarity region of the second oligonucleotide comprises a 3′ end of the second oligonucleotide,
(x) the fourth complementarity region of the second oligonucleotide is adjacent to the sixth complementarity region of the second oligonucleotide or any combination thereof.

13. The method of claim 1 , wherein
(i) a third oligonucleotide is configured to decode bases; and
(ii) a fourth oligonucleotide is configured to convert the decoded bases into a signal.

14. The method of claim 1 , wherein the imaging comprises imaging the one or more amplicons that are embedded in hydrogel using a microscopy selected from the group consisting of confocal microscopy, widefield fluorescence microscopy, two-photon microscopy, light-field microscopy, intact tissue expansion microscopy, super-resolution microscopy, and light sheet microscopy.

15. The method of claim 14 , wherein the light sheet microscopy is CLARITY-optimized light sheet microscopy (COLM).

16. The method of claim 1 , wherein the tissue has a thickness of 5 micrometers (μm) to 20 μm.

17. The method of claim 1 wherein the tissue is a thick slice having a thickness of 5 μm to 200 μm.

18. A method of screening a candidate agent to determine whether the candidate agent modulates gene expression of the nucleic acid in the cell in the tissue, comprising: performing the method of claim 1 to determine gene sequencing of the nucleic acid in the cell in the tissue, and
detecting a level of gene expression of the nucleic acid, wherein an alteration in the level of gene expression of the nucleic acid in the presence of the candidate agent relative to the level of expression of the nucleic acid in the absence of the at least one candidate agent indicates that the at least one candidate agent modulates gene expression of the nucleic acid in the cell in the tissue.

19. The method of claim 18 , wherein the detecting comprises determining a signal.

20. The method of claim 19 , wherein the signal is a fluorescent signal.

21. The method of claim 1 , further comprising adding a ligase to ligate a first end of the second oligonucleotide to a second end of the second oligonucleotide thereby generating a closed nucleic acid circle.

22. The method of claim 21 , wherein the ligase is a DNA ligase.

23. The method of claim 1 , wherein the amplification reaction comprises rolling circle amplification, and wherein the second oligonucleotide is a template and the first oligonucleotide is a primer for a polymerase to form one or more amplicons.

24. The method of claim 1 , wherein the one or more amplicons is embedded in the hydrogel after the amplification reaction of (b).

25. The method of claim 1 , wherein the one or more amplicons is embedded in the hydrogel by copolymerizing the one or more amplicons with acrylamide.

26. The method of claim 1 , wherein the tissue is embedded in the hydrogel prior to (b).

27. The method of claim 1 , wherein the first portion of the nucleic acid and the second portion of the nucleic acid are separated by one or more nucleotides.

28. The method of claim 1 , wherein the first complementarity region is adjacent to the fifth complementarity region.

Assignees

• Univ Leland Stanford Junior

Inventors

• Wang Xiao
• Allen William E
• Deisseroth Karl A

Classifications

• C12Q1/6841

  In situ hybridisation · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12Q2600/136

  Screening for pharmacological compounds · CPC title

• C12Q1/6876

  Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes · CPC title

• C12Q2563/107

  fluorescence · CPC title